Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Key Documents

View All Documentation

919454

Sigma-Aldrich

CCW16-PEG3-BocNH

≥95%

Synonyme(s) :

tert-Butyl (2-(2-(2-(2-(4-(4-(N-Benzyl-2-chloroacetamido)phenoxy)phenoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamate, Crosslinker-E3 Ligase ligand conjugate, Protein degrader building block for PROTAC® research, RNF4-targeting building block, Template for synthesis of targeted protein degrader

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C34H43ClN2O8
Poids moléculaire :
643.17
Nomenclature NACRES :
NA.22

ligand

CCW16

Niveau de qualité

100

Pureté

≥95%

Forme

liquid

Pertinence de la réaction

reactivity: carboxyl reactive
reagent type: ligand-linker conjugate

Groupe fonctionnel

amine

Température de stockage

2-8°C

Chaîne SMILES 

O=C(CCl)N(CC1=CC=CC=C1)C2=CC=C(C=C2)OC3=CC=C(OCCOCCOCCOCCNC(OC(C)(C)C)=O)C=C3

Catégories apparentées

Application

Protein degrader building block CCW16-PEG3-BocNH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a RING finger protein 4 (RNF4)-recruiting ligand, a PEGylated crosslinker, and a pendant amine for reactivity with a carboxylic acid on the target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a terminal amine, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Autres remarques

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC® Degraders for Targeted Protein Degradation

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Informations légales

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

901495

Pomalidomide-PEG3-NH2 hydrochloride, ≥95%

901511

(S,R,S)-AHPC-PEG3-NH2 hydrochloride, ≥95%

901504

Pomalidomide-PEG3-CO2H, ≥95%

901533

(S,R,S)-AHPC-PEG3-Alkyne, ≥95%

901531

Pomalidomide-PEG3-Alkyne, ≥95%

904651

(S,R,S)-AHPC-PEG3-azide, ≥95%

904678

Pomalidomide-PEG3-azide

911747

C5 Lenalidomide-PEG3-NH2 hydrochloride, ≥95%

917680

BocA1V1PF2-OPEG3-NH2 hydrochloride

917702

A1V2PF1-NHEt-PEG3-NH2

917214

BocA1V2PF1-NHPEG3-NH2, ≥85%

916676

A1V1PF2-OEt-PEG3-NH2 hydrochloride

916692

BocA1V2PF2-NHPEG3-NH2, ≥95%

917192

A1V2PF2-NHEt-PEG3-NH2, ≥95%

919438

CCW16-C9-BocNH, ≥95%

919470

CCW16-PEG2-butyl-BocNH, ≥95%

919462

CCW16-PEG5-BocNH, ≥95%

919403

CCW16-C4-BocNH, 95%

919446

CCW16-PEG1-BocNH

919489

CCW16-C6-PEG3-butyl-BocNH

919411

CCW16-C6-BocNH

919381

CCW16, ≥95%

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique